1999 47:23–30.Healthcare in the United States has dominated the social, political, and financial arena in the past decade. The therapeutic monitoring of antimicrobial agents.
Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. Tsutsuura M, Moriyama H, Kojima N, et al. Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, the IATDMCT Anti-Infectives Committee, provides recommendations with respect to best clinical practice for vancomycin TDM.Ĭopyright © 2021 Wolters Kluwer Health, Inc. Ultimately, TDM data in the clinical context of the patient and their response to treatment should guide vancomycin therapy. Adequate documentation of sampling, correct storage and transport, accurate laboratory analysis, and pertinent data reporting are required to ensure appropriate interpretation of TDM data to guide vancomycin dosing recommendations. It is acknowledged that there may be institutional barriers to the implementation of AUC24-guided dosing, and additional effort is required to enable the transition from trough-based to AUC24-based strategies. There is increasing evidence to support area-under-the-curve (AUC24)-guided TDM to inform vancomycin dosing decisions for patients receiving therapy for more than 48 hours. Individualization of vancomycin dosing based on therapeutic drug monitoring (TDM) data is known to improve patient outcomes compared with fixed or empirical dosing strategies. 16 Department of Clinical Microbiology and Infectious Diseases, St Vincent's Hospital, Sydney, Australia.15 Institute for Clinical Pathology and Medical Research, NSW Health Pathology, Sydney, Australia and.14 Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, Australia.13 Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.12 Department of Pediatrics, Keck School of Medicine, University of Southern California, and Division of Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, California, Los Angeles, CA.11 Department of Diagnostic Medicine, Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.10 Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, India.9 Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, The Netherlands.8 Department of Chemical Pathology and Clinical Pharmacology, SydPath, St Vincent's Hospital, Sydney, Australia.7 Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.6 Marie Bashir Institute of Infectious Diseases and Biosecurity, The University of Sydney, Sydney, Australia.5 Department of Pharmacy, Westmead Hospital, Sydney, Australia.4 St Vincent's Clinical School, Faculty of Medicine, The University of New South Wales, Sydney, Australia.3 Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, Australia.2 Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.1 UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
0 kommentar(er)
